ANI Pharmaceuticals, Inc.

ANIP Healthcare Drug Manufacturers Specialty & Generic

ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024. In the quarter to June 2026, revenue grew 25.9%, EPS grew 194.6%, free cash flow fell 22.2% and total debt fell 1.78%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

72.08 0.20 −0.28%
Market cap
$1.7B
P/E
14.9×
Fwd P/E
14.5×
Dividend yield
—
F-score
7/9
Altman Z
2.30
Beneish M
−2.62
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

53.57 22.55 18.71 17.14
P/S ratio
2.22 1.79 1.74 1.79
P/FCF ratio
13.59 10.49 8.80 10.46
P/Operating CF
41.74 52.13 27.55 30.91
P/B ratio
3.64 2.93 2.86 2.93
Price to Tangible BV
0.00 0.00 49.24 20.64
EV/Sales
2.65 2.16 2.05 2.03
EV/EBITDA
12.59 9.41 8.89 8.41
EV/Operating CF
12.81 10.29 9.09 10.48
EV/FCF
16.17 12.63 10.37 11.86
Quick Ratio
1.94 2.07 2.43 2.29
Current Ratio
2.58 2.71 3.12 2.91
Net Debt/EBITDA
5.92 5.62 4.81 3.90
Debt/Assets
44.05% 42.84% 43.16% 40.86%
Debt/Equity
1.23 1.14 1.09 1.02
Asset Turnover
0.61 0.65 0.68 0.69
Operating CF/Net income
1.68 1.10 1.98 2.29
Capex/Depreciation
(0.27) (0.06) (0.54) (0.16)
Interest Coverage
7.67 7.88 10.32 11.13
Research and Development Expense of Revenue
5.40% 4.96% 4.46% 5.54%
Selling, General and Administrative Expense of Revenue
33.65% 33.51% 31.02% 34.45%
Intangible Assets out of Total Assets
0.40 0.38 0.37 0.34
Share Based Compensation of Revenue
4.25% 3.95% 4.29% 4.29%
Graham Net Nets
(0.11) (0.09) (0.07) (0.04)
Graham Number
31.14 46.08 49.86 55.39
Earnings Yield
1.87% 4.43% 5.34% 5.83%
Free Cash Flow Yield
7.36% 9.53% 11.37% 9.56%
Revenue per Share
11.35 12.32 11.35 12.57
Operating CF per Share
2.19 1.51 2.79 2.68
Capex per Share
(0.31) (0.07) (0.54) (0.14)
Free Cash Flow per Share
1.89 1.44 2.25 2.53
Cash per Share
13.53 14.70 15.59 17.77
Shareholders Equity per Share
25.20 26.96 26.89 28.23
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
25.20 26.96 26.89 28.23
Free Cash Flow
37.89 28.96 47.05 53.62
Working Capital
427.85 475.01 507.57 541.78
Capital Expenditures
(6.16) (1.40) (11.32) (3.05)
Net Current Asset Value
(203.93) (146.54) (112.59) (71.47)
EV/EBIT
30.41 17.15 15.32 13.21
Capex to Sales
0.03 0.01 0.05 0.01
Price to Operating Income
25.56 14.25 12.99 11.65
Other line items
Average Receivables
224.49 251.40 237.88 250.06
Average Payables
65.34 54.12 61.38 64.20
Average Inventory
147.26 139.92 140.44 140.73
Average Assets
1,347.76 1,362.42 1,357.20 1,418.56
Average Common Equity
455.88 472.20 490.46 516.98

Fold the line items

Columns are period end dates